[{"id":"b5433020-6fcb-49f0-a449-5146dab9a586","acronym":"IntReALL SR 2010","url":"https://clinicaltrials.gov/study/NCT01802814","created_at":"2021-01-18T07:59:00.034Z","updated_at":"2024-07-02T16:35:19.923Z","phase":"Phase 3","brief_title":"International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010","source_id_and_acronym":"NCT01802814 - IntReALL SR 2010","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 700","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2024-02-09"},{"id":"f0b16bd4-2299-4f27-bcd2-cf5b95504933","acronym":"","url":"https://clinicaltrials.gov/study/NCT00301821","created_at":"2021-01-18T01:01:58.571Z","updated_at":"2024-07-02T16:36:54.751Z","phase":"Phase 2","brief_title":"Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT00301821","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD22","pipe":"","alterations":" ","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 10/01/2008","primary_completion_date":" 10/01/2008","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2019-10-09"},{"id":"497ad865-d158-4d01-a639-cc3e564d7ce0","acronym":"CHEPRALL","url":"https://clinicaltrials.gov/study/NCT01219816","created_at":"2021-01-18T04:53:56.318Z","updated_at":"2024-07-02T16:37:13.463Z","phase":"Phase 2","brief_title":"Multi-centric Study","source_id_and_acronym":"NCT01219816 - CHEPRALL","lead_sponsor":"Nantes University Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2018-02-27"},{"id":"0801a37d-ac3b-4a5e-9b77-5d3a907cee08","acronym":"","url":"https://clinicaltrials.gov/study/NCT00098839","created_at":"2021-01-18T00:18:44.126Z","updated_at":"2024-07-02T16:37:15.583Z","phase":"Phase 2","brief_title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT00098839","lead_sponsor":"Children's Oncology Group","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Marqibo (vincristine liposomal) • Epratucyn (epratuzumab) • Neupogen (filgrastim) • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 02/01/2005","start_date":" 02/01/2005","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 04/01/2011","study_completion_date":" 04/01/2011","last_update_posted":"2017-12-12"},{"id":"8b50b7e9-7468-4a63-8f8b-5dddd813e679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00945815","created_at":"2021-01-18T03:40:26.168Z","updated_at":"2024-07-02T16:37:16.636Z","phase":"Phase 2","brief_title":"S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00945815","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD22 • CD33 • CD4 • ANPEP","pipe":"","alterations":" ","tags":["CD22 • CD33 • CD4 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • clofarabine • Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-11-06"},{"id":"015a4b5c-9024-44cd-bf9c-680f009004a6","acronym":"EPRALLO","url":"https://clinicaltrials.gov/study/NCT02577094","created_at":"2021-01-18T12:29:58.002Z","updated_at":"2024-07-02T16:37:26.429Z","phase":"Phase 1/2","brief_title":"Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02577094 - EPRALLO","lead_sponsor":"Nantes University Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • Epratucyn (epratuzumab) • LymphoCide Y-90 (epratuzumab Y-90)"],"overall_status":"Withdrawn","enrollment":"","initiation":"","start_date":"","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2017-01-19"},{"id":"f3acea0e-0cd9-441e-9f39-6f76c3cf9a2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553501","created_at":"2021-01-18T02:00:59.729Z","updated_at":"2024-07-02T16:37:30.864Z","phase":"Phase 2","brief_title":"Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00553501","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Epratucyn (epratuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-07-06"}]